Black Hawk SPAC enters $70M merger with Vesicor Therapeutics; p53 cancer therapy focus

Black Hawk Acquisition Corp

Total equity value $70M; Aggregate Merger Consideration = $70M divided by Redemption Price.
Vesicor must secure at least $10M in PIPE financing as condition to close.
Post-merger CEO: Luo Feng, CFO: Michael Bowen, COO: Warren Hosseinion Jr.; 5-member board.
Lock-up: 6 months for PubCo shares, 12 months for Vesicor warrant holders.
Break-up fee of $1M payable by breaching party; termination rights for failure to secure PIPE or deliver audited financials by June 10, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.